Boehringer Ingelheim has partnered with South Korea-based Yuhan for the development of a first-in-class compound to treat nonalcoholic steatohepatitis (NASH) and other related liver disorders.
South Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.